Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2026

Conditions
Metastatic Melanoma
Interventions
DRUG

AV-MEL-1

AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.

Trial Locations (2)

92618

RECRUITING

Jericho Rabago, Irvine

92663

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors
All Listed Sponsors
lead

Aivita Biomedical, Inc.

INDUSTRY